REGROWTH — OR RISK?

February 13, 2026

Share this article

The financier behind a global stem-cell venture — and a decades-long trail of collapsed companies.

Behind the glossy language of regenerative wellness and cutting-edge therapies lies a financial backstory few patients are likely to see.


An investigation into the business history of Max Robert Lewinsohn, a key financial figure linked to Wellbeing International Foundation, reveals a career shaped not by medicine — but by a succession of ambitious investment ventures, many of which ended in liquidation, administration, or legal dispute.


None of those historic collapses relate directly to clinical treatment. But as thousands of clients worldwide place significant trust — and often large sums of money — into privately funded regenerative programmes, the financial history of those controlling the funding structures has become an increasingly urgent question.


A FINANCIER IN A MEDICAL WORLD


Lewinsohn’s professional background sits firmly in accountancy, investment, and corporate finance. Records show a career spanning property, oil & gas, technology and international investment vehicles — sectors far removed from clinical science.

Today, however, he occupies a prominent leadership and financial role within an organisation promoting regenerative therapies to a global audience.

For critics of the industry, that crossover raises a critical issue: when financiers rather than clinicians sit at the centre of healthcare-adjacent ventures, where does accountability ultimately lie?


THE FIRST COLLAPSE: DOMINION INTERNATIONAL


One of the earliest controversies dates back to Dominion International Group Plc, where Lewinsohn served as chairman before being forced to resign in 1988 following accusations of mismanagement by fellow shareholders.

Within a year, Dominion entered administration with liabilities reportedly exceeding assets by approximately £100 million. Contemporary reports suggested internal reviews revealed the company’s financial position to be significantly worse than previously disclosed.

Media coverage at the time referenced potential interest from the Serious Fraud Office, although no confirmed investigation has been identified in available public records.

The episode marked the beginning of a pattern critics say would define later ventures: bold investment strategies followed by financial instability.


DISPUTES, RESIGNATIONS AND DISCIPLINARY ACTION


Subsequent roles across companies including Southwest Resources Plc and Card Clear Ltd were also marked by controversy.

  • He was dismissed from Southwest Resources amid financial difficulties.
  • He resigned from Card Clear following criticism over investor disclosures.

Historical reporting also describes proposed director disqualification proceedings linked to a disputed overseas acquisition. While appeals appear to have complicated the final outcome — and definitive online records remain limited — available information indicates he was banned from membership of the Institute of Chartered Accountants following related allegations.

Supporters argue that decades in venture finance inevitably involve failed projects. Critics counter that the frequency of troubled ventures is unusually high.


ENECO INC.: PROMISES THAT ENDED IN BANKRUPTCY


Between 1997 and 2007, Lewinsohn chaired Eneco Inc., a US-based energy technology company that ultimately filed for bankruptcy in 2008.

Litigation following the collapse resulted in court orders requiring him to contribute toward legal costs arising from disputes over company debts.

For governance analysts, Eneco represents another example of a pattern: ambitious projects attracting investment before ending in financial collapse.


NEW FINDINGS: ANOTHER DIRECTORSHIP FALLS INTO LIQUIDATION


Fresh documents obtained by this investigation show that MicroPower Global Markets Limited, a company associated with Lewinsohn’s more recent business activities, has also entered Creditors’ Voluntary Liquidation.

Official filings confirm the company moved through insolvency proceedings during 2025, with the liquidator’s final account now filed ahead of dissolution. 

application-pdf

Financial summaries indicate that at the time of winding-up the company held just £1,016.85 in cash while creditor claims exceeded £246,000, leaving no funds available for unsecured creditors. 

application-pdf

Corporate failures occur across many industries. Yet when viewed alongside earlier ventures, the latest liquidation adds to a timeline that investigators say warrants closer scrutiny.


WHY THIS MATTERS TO CLIENTS


This investigation has uncovered no direct evidence linking any liquidation to patient funds or clinical operations.

However, consumer-protection experts say the financial histories of major backers become highly relevant when healthcare-adjacent ventures rely heavily on upfront payments from clients seeking emerging treatments.

One regulatory analyst explained:


“Patients don’t always realise that behind the medical branding may sit investors with long histories in high-risk ventures. Transparency becomes critical when large sums are involved.”


A PATTERN — OR COINCIDENCE?


Supporters may argue that Lewinsohn’s career reflects the realities of venture capitalism, where high-risk innovation inevitably produces failures alongside successes.


Critics, however, describe a recurring pattern:

  • Ambitious investment structures
  • Aggressive expansion into emerging sectors
  • Companies ending in insolvency, litigation, or liquidation


With another directorship now formally wound up, questions surrounding governance and oversight are likely to intensify — particularly as the global regenerative-therapy market continues to expand under increasing regulatory pressure.


Recent Posts

May 15, 2026
For months, investigators have examined the digital footprint, corporate structure, public marketing, and leadership profiles connected to Wellbeing International Foundation Ltd.
May 15, 2026
As investigators continued examining the structure behind Wellbeing International Foundation Ltd,
May 10, 2026
WELLBEING INTERNATIONAL FOUNDATION TESTIMONIALS
May 10, 2026
WELLBEING INTERNATIONAL FOUNDATION LTD: “ETHICAL HEALING”
May 3, 2026
The commercial stem cell industry has grown rapidly over the past decade, with clinics around the world advertising regenerative medicine programs for conditions ranging from chronic pain to neurological disorders. Among the most controversial areas is autism. Families searching online are now routinely exposed to clinics promoting stem cell therapies as potential solutions for behavioural, developmental, or communication difficulties associated with autism spectrum disorder (ASD). But according to major medical authorities, parents should be extremely careful before committing to expensive experimental treatments. No Major Regulator Has Approved Stem Cell Therapy For Autism At present: The U.S. Food and Drug Administration has not approved stem cell therapy as a treatment for autism. The National Health Service does not recognise stem cell therapy as a standard autism treatment. European regulators continue treating most autism-related stem cell therapies as experimental. Researchers continue studying the field. But experimental science and established medical treatment are not the same thing. The Problem With Commercial Marketing Critics argue that some clinics blur the line between scientific possibility and proven outcome. Common marketing techniques include: Emotional recovery stories Before-and-after videos Technical medical language Claims of “advanced” therapy References to inflammation or neurological repair However, many scientists say evidence supporting these claims remains limited or inconclusive. Understanding Autism Complexity Autism is not a single illness. It is a broad developmental spectrum involving: Communication differences Behavioural traits Sensory variation Neurological diversity Because autism naturally develops differently in every child, measuring treatment success becomes highly complicated. Experts warn that developmental progress may sometimes occur naturally over time regardless of experimental intervention. What Treatments Have Better Scientific Support? While no treatment cures autism, specialists generally recommend evidence-based support approaches such as: Speech and language therapy Occupational therapy Behavioural intervention Educational support Social development programs Family support services Major organisations providing evidence-based information include: National Autistic Society https://www.autism.org.uk/ Centers for Disease Control and Prevention https://www.cdc.gov/autism/ World Health Organization https://www.who.int/ Autism Speaks https://www.autismspeaks.org/ Questions Families Should Ask Before Paying Experts recommend parents ask: Is this treatment regulator-approved? What peer-reviewed evidence exists? What are the known risks? What percentage of patients show no benefit? Are claims independently verified?  Evidence Before Emotion Families searching for hope deserve compassion, transparency, and honesty. Stem cell science remains an active research field. But until stronger clinical evidence exists, many experts believe autism-related stem cell treatments should be approached with serious caution — particularly when large sums of money and vulnerable families are involved.
May 3, 2026
As commercial stem cell clinics continue expanding across Europe and beyond, increasing numbers of families affected by autism are being introduced to expensive regenerative medicine programs marketed as cutting-edge alternatives to conventional therapy. One organisation repeatedly mentioned during conversations with former clients and concerned families is Wellbeing International Foundation LTD. This article does not accuse the clinic of criminal behaviour or fraud. However, as concerns surrounding commercial autism-related stem cell treatments continue growing internationally, experts say families should approach all such clinics with careful scrutiny. Why Autism Has Become A High-Interest Market Autism spectrum disorder affects millions of families worldwide. Because there is no single cure — and because developmental progress can vary enormously from child to child — families are often vulnerable to treatments marketed as innovative or revolutionary. Investigators reviewing the regenerative medicine sector have identified repeated themes in clinic advertising: Hope-based messaging Emotional testimonials Scientific jargon “Breakthrough” language Claims of advanced neurological repair Large financial commitments For many parents, distinguishing between genuine science and commercial optimism can become extremely difficult. THE MAIN WARNING SIGNS 🚩 Clinics Suggesting One Treatment Can Help Many Conditions Experts urge caution when the same therapy is promoted for: Autism Neurological disease Chronic pain Anti-ageing Immune conditions Degenerative illness Complex medical conditions require highly specific evidence. 🚩 Testimonials Used As Primary Evidence Powerful personal stories can influence emotions deeply. But regulators repeatedly warn that testimonials alone do not prove clinical effectiveness. 🚩 Scientific Terminology Without Clear Proof Families should ask clinics to clearly explain: How treatments work What evidence exists What outcomes are independently verified Complicated language is not the same as scientific certainty. 🚩 Significant Financial Commitments Many families report spending very large sums on: Consultations Treatment programs Flights Accommodation Repeat procedures without guaranteed outcomes. 🚩 Overseas Structures And Limited Oversight International treatment arrangements can complicate: Legal accountability Consumer rights Medical regulation Long-term follow-up The Ethics Of Hope Medical ethics experts have increasingly raised concerns about the emotional vulnerability of families searching for autism support. Parents naturally want to help their children. That emotional reality can make high-promise treatments especially persuasive. Critics argue that hope should never be marketed in a way that risks creating unrealistic expectations.  Questions Families Should Always Ask Before committing to any stem cell-based autism treatment, families should request: Published evidence Independent clinical data Long-term outcomes Full risk disclosures Regulatory status information Transparency matters. Especially when vulnerable families are involved.
May 3, 2026
For many parents raising children with autism, life becomes a constant search for answers. Therapies. Specialists. Diets. Support groups. New research. Alternative medicine. And increasingly, stem cell clinics. Over recent months, Investigations Desk has spoken with families who say they pursued expensive regenerative medicine treatments for autistic children after being exposed to persuasive marketing campaigns promising potential improvements in communication, behaviour, focus, and cognitive function. One parent — who we will identify only as Mr X to protect the child’s privacy — described a journey that began with optimism but eventually turned into doubt. According to Mr X, the family underwent multiple treatment procedures after being encouraged to believe stem cell-based therapies could potentially assist with autism-related symptoms. Initially, every small behavioural change felt significant. But over time, the family says they began questioning whether the treatments had actually produced any measurable improvement at all. “You want to believe something is happening,” Mr X explained. “As a parent, you analyse every little change because you desperately want your child to improve.” The family says the emotional pressure surrounding the process made objective judgment increasingly difficult. The Rise Of Autism As A Commercial Treatment Market Autism spectrum disorder has become one of the fastest-growing target areas within the global regenerative medicine industry. Across websites and social media platforms, clinics frequently advertise: Stem cell therapy Exosome therapy Neuro-regenerative medicine Immune modulation programs Cellular repair treatments Many use emotional testimonials alongside highly technical scientific language which can be difficult for ordinary families to independently verify. Investigators examining this sector have repeatedly identified recurring marketing patterns: Dramatic recovery stories Scientific terminology with limited explanation Expensive treatment packages Overseas treatment arrangements “Breakthrough” medical language Claims that conventional medicine is “behind” What Science Currently Says Despite aggressive online marketing, there is currently no universally accepted regulator-approved stem cell cure for autism. Research into stem cells and neurological conditions does exist. However, leading experts continue warning that experimental research should not be confused with established medical treatment. Autism itself is an extremely complex developmental condition involving a broad spectrum of behavioural and neurological differences. That complexity makes it particularly difficult to scientifically measure treatment claims being promoted commercially. Hope And Vulnerability Parents affected by autism are not foolish for exploring possibilities. They are hopeful. And hope can become extremely powerful when families feel conventional support systems are slow, limited, or overwhelmed. Critics of the commercial stem cell industry argue that some clinics may unintentionally blur the line between experimental science and proven medical outcomes. That concern is now drawing increasing international attention from regulators, scientists, and consumer protection groups.  The Bigger Question Mr X says the family eventually decided to speak privately with investigators after recognising similarities between their experience and concerns now being raised globally about commercial regenerative medicine businesses. “We’re not against research,” he said. “But families need to know the difference between evidence and hope.” That distinction may now sit at the heart of one of the most controversial debates in modern alternative medicine.
April 24, 2026
There is a pattern. Once you’ve seen it, you can’t unsee it.
Show More